Phase II clinical trial - Appareil pulmonaire
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).;Telisotuzumab vedotin (ABBV-399) is an antiÀc-Met antibody drug;conjugate (ADC) for the treatment of c-MetÀoverexpressing solid;tumors. The pharmacology, toxicology, and pharmacokinetic profiles;of telisotuzumab vedotin were adequately characterized to support;initiation of a Phase 2 clinical trial in subjects with locally advanced or;metastatic non-small cell lung cancer (NSCLC). The non-clinical and;clinical data together reflect an acceptable rationale for continued;treatment of adult subjects with advanced cancer with telisotuzumab;vedotin within the context of a clinical trial.